Catalent Biologics' Limoges, France site is our European center of excellence for early phase clinical biologics formulation development and drug product fill/finish. The site offers an integrated facility with a small-scale filling line, in-house analytical capabilities, quality control labs, cold storage, and regulatory support.

Summary: For Contract Development and Manufacturing Organizations (CDMOs), transitioning to Biopharma 4.0 is crucial – the data and expertise amassed by these manufacturers represent an integral asset for their customers working to innovate in an increasingly competitive and fast-paced market.

This article describes the benefits of transitioning from IV to SQ administration, considers the advantages of using PFSs, and explores challenges and solutions for transitioning from vials to PFS.

Summary: In this podcast, experts discuss how to overcome obstacles that span from discovery to launch of orphan drugs as well as discuss the needs of patients and drug developers in orphan biologics development.

Summary: In this webinar, experts discuss the formulation development challenges, considerations, and potential solutions associated with...

Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure...

Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s "A Look Ahead at Biotech in 2022" event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.

Summary: On December 13, 2021, EuropaBio hosted the final event of its 25th Anniversary programme with a focus on the story of mRNA.

Summary: Supply chains have come under intense pressure, and companies have had to adapt to this “new normal” to avoid delays. During this Q&A, Catalent discusses....

Summary: Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.